Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186352 | 0.83 | HDAC2 (0.72) | HPGDHDAC1HDAC8MEN1KMT2A | |
| SCHEMBL12470057 | 0.81 | ACACB (0.50) | HPGDHTTCA1CA2 | |
| SCHEMBL12246765 | 0.80 | TAAR1 (0.56) | HPGDHDAC1HDAC8MEN1KMT2A | |
| SCHEMBL4151976 | 0.79 | GAA (0.74) | HPGDHDAC1HDAC8MEN1KMT2A | |
| SCHEMBL4151866 | 0.79 | GAA (0.74) | HPGDHDAC1HDAC8MEN1KMT2A | |
| SCHEMBL13401878 | 0.79 | CA1 (0.80) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL28153879 | 0.79 | ALDH1A1 (0.61) | PTPN1HDAC1HDAC8HDAC4CA1 | |
| SCHEMBL6803371 | 0.78 | CNR1 (0.58) | MEN1KMT2AHTTPOLB | |
| SCHEMBL7765076 | 0.78 | L3MBTL1 (0.79) | HPGDHDAC1HDAC8HDAC4HDAC3 | |
| SCHEMBL15679869 | 0.78 | PLAAT3 (0.73) | HPGDHDAC1HDAC8KMT2AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Aerpio Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-01-25 | — | — | US | disclosed |
| US-9795594-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160374996-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2016-12-29 | — | — | US | disclosed |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| EP-2967066-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150210656-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2015-07-30 | — | — | US | disclosed |
| WO-2014145068-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2624916-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | Aerpio Therapeutics Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012047966-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AKEBIA THERAPEUTICS INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPN1 62/4885HPGD 2697/4885HDAC1 2399/4885 |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPN1 62/4885HPGD 2697/4885HDAC1 2399/4885 |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPN1 2139/4885HPGD 584/4885HDAC1 3177/4885 |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPN1 2139/4885HPGD 584/4885HDAC1 3177/4885 |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPN1 2139/4885HPGD 584/4885HDAC1 3177/4885 |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPN1 2139/4885HPGD 584/4885HDAC1 3177/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPN1 2139/4885HPGD 584/4885HDAC1 3177/4885 |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPN1 62/4885HPGD 2697/4885HDAC1 2399/4885 |
| US-20150210656-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPN1 62/4885HPGD 2697/4885HDAC1 2399/4885 |
| US-20160374996-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPN1 62/4885HPGD 2697/4885HDAC1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.